Ose immuno press release
WebApr 5, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 8 June 2016 under the number R.16-052, the ... WebMar 30, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF …
Ose immuno press release
Did you know?
WebSep 2, 2014 · focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immune-oncology and auto-immune diseases. WebSep 22, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2024, including the...
WebOct 11, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2024, including the... WebThis press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 28 April 2024 under the …
WebFeb 15, 2024 · OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the company has signed a loan agreement of up to €25 million with the … WebMar 15, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2024, including the...
WebJun 23, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF …
WebOct 7, 2024 · OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) is pleased to announce the appointment of Dr. Nicolas Poirier as new Chief Executive Officer, effective immediately.... la perle dubai seating planWebMar 11, 2024 · Immuno-oncology platform. BI 765063 (OSE-172, anti-SIRPα mAb on SIRPα/CD47 pathway): ... This press release includes only summary information and … la perle du danubeWebApr 26, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF … la perleraieWebFeb 22, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF … la perle du verdon parkingWebFeb 15, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2024, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. la perle ris orangisWebJul 13, 2024 · NANTES, France, July 13, 2024 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately. Alexis Vandier brings an impressive track record of successes in Pharma across a range of … la perle dubaiWebSep 30, 2024 · This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2024, including the... la perle sardines